Schein
Executive Summary
Subsidiary Marsam Pharmaceuticals receives Form 483 from FDA on July 29. Company will revise initial corrective action plan focusing on procedures, systems control and retraining revisions, and will hire an independent consultant for evaluation. After a voluntary recall on 14 Marsam products, Schein contracted out manufacturing of a cephalosporin antibiotic (1"The Pink Sheet" Jun. 28, p. 33). Schein is currently looking for other opportunities to outsource additional drugs
Subsidiary Marsam Pharmaceuticals receives Form 483 from FDA on July 29. Company will revise initial corrective action plan focusing on procedures, systems control and retraining revisions, and will hire an independent consultant for evaluation. After a voluntary recall on 14 Marsam products, Schein contracted out manufacturing of a cephalosporin antibiotic (1 (Also see "Marsam recalls" - Pink Sheet, 28 Jun, 1999.)). Schein is currently looking for other opportunities to outsource additional drugs. |